Bank of America Corp DE increased its position in Atrion Co. (NASDAQ:ATRI) by 58.4% in the 4th quarter, Holdings Channel reports. The firm owned 982 shares of the medical instruments supplier’s stock after buying an additional 362 shares during the period. Bank of America Corp DE’s holdings in Atrion were worth $727,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. purchased a new stake in shares of Atrion in the 4th quarter valued at about $130,000. Quantamental Technologies LLC purchased a new stake in shares of Atrion in the 4th quarter valued at about $149,000. Wesbanco Bank Inc. purchased a new stake in shares of Atrion in the 4th quarter valued at about $259,000. Principal Financial Group Inc. lifted its holdings in shares of Atrion by 27.8% in the 4th quarter. Principal Financial Group Inc. now owns 368 shares of the medical instruments supplier’s stock valued at $273,000 after purchasing an additional 80 shares during the last quarter. Finally, Citigroup Inc. raised its stake in Atrion by 20.7% during the 4th quarter. Citigroup Inc. now owns 437 shares of the medical instruments supplier’s stock valued at $324,000 after acquiring an additional 75 shares during the last quarter. 61.54% of the stock is owned by institutional investors and hedge funds.

ATRI opened at $901.70 on Friday. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 46.98 and a beta of 0.42. Atrion Co. has a 52 week low of $560.65 and a 52 week high of $948.03.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Tuesday, February 26th. The medical instruments supplier reported $4.17 EPS for the quarter. The firm had revenue of $34.93 million during the quarter. Atrion had a return on equity of 16.89% and a net margin of 22.76%.

Several research firms have commented on ATRI. BidaskClub downgraded Atrion from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 2nd. ValuEngine raised Atrion from a “hold” rating to a “buy” rating in a research note on Monday, February 4th.

TRADEMARK VIOLATION NOTICE: “Bank of America Corp DE Boosts Stake in Atrion Co. (ATRI)” was published by Marea Informative and is the property of of Marea Informative. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.mareainformativa.com/news/2019/05/17/bank-of-america-corp-de-boosts-stake-in-atrion-co-atri.html.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: 52-Week High/Low

Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI).

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.